Last Updated: September 24, 2026

Details for New Drug Application (NDA): 206627

✉ Email this page to a colleague

NDA 206627 describes HYSINGLA ER, which is a drug marketed by Knoa Pharma and is included in one NDA. It is available from one supplier. There are nineteen patents protecting this drug and two Paragraph IV challenges. Additional details are available on the HYSINGLA ER profile page.

The generic ingredient in HYSINGLA ER is hydrocodone bitartrate. There is one drug master file entry for this compound. Two suppliers are listed for this compound. Additional details are available on the hydrocodone bitartrate profile page.

Summary for 206627

Tradename:	HYSINGLA ER
Applicant:	Knoa Pharma
Ingredient:	hydrocodone bitartrate
Patents:	19

Pharmacology for NDA: 206627

Mechanism of Action	Opioid Agonists

Medical Subject Heading (MeSH) Categories for 206627

Analgesics, Opioid
Antitussive Agents
Narcotics

Suppliers and Packaging for NDA: 206627

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
HYSINGLA ER	hydrocodone bitartrate	TABLET, EXTENDED RELEASE;ORAL	206627	NDA	Knoa Pharma LLC	59011-271	59011-271-60	60 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (59011-271-60)
HYSINGLA ER	hydrocodone bitartrate	TABLET, EXTENDED RELEASE;ORAL	206627	NDA	Knoa Pharma LLC	59011-272	59011-272-60	60 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (59011-272-60)

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	TABLET, EXTENDED RELEASE;ORAL			Strength	20MG
Approval Date:	Nov 20, 2014	TE:	AB	RLD:	Yes
Patent:	⤷ Start Trial	Patent Expiration:	Aug 24, 2027	Product Flag?	Y	Substance Flag?		Delist Request?
Patent:	⤷ Start Trial	Patent Expiration:	Aug 24, 2027	Product Flag?		Substance Flag?		Delist Request?
Patented Use:	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
Patent:	⤷ Start Trial	Patent Expiration:	Dec 21, 2031	Product Flag?	Y	Substance Flag?		Delist Request?
Patented Use:	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE

Expired US Patents for NDA 206627

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Knoa Pharma	HYSINGLA ER	hydrocodone bitartrate	TABLET, EXTENDED RELEASE;ORAL	206627-002	Nov 20, 2014	⤷ Start Trial	⤷ Start Trial
Knoa Pharma	HYSINGLA ER	hydrocodone bitartrate	TABLET, EXTENDED RELEASE;ORAL	206627-002	Nov 20, 2014	⤷ Start Trial	⤷ Start Trial
Knoa Pharma	HYSINGLA ER	hydrocodone bitartrate	TABLET, EXTENDED RELEASE;ORAL	206627-002	Nov 20, 2014	⤷ Start Trial	⤷ Start Trial
Knoa Pharma	HYSINGLA ER	hydrocodone bitartrate	TABLET, EXTENDED RELEASE;ORAL	206627-006	Nov 20, 2014	⤷ Start Trial	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.